Home / HIV/AIDS

HIV/AIDS

Janssen Reports Positive Topline Results for Phase 3 Study of Long Acting Injectable Two-Drug Regimen for Treatment of HIV

CORK, Ireland, Aug. 15, 2018  /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today confirmed positive topline results from the global, Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) study of the first investigational long-acting injectable two-drug regimen (2DR) for the treatment of HIV-1. The ATLAS study results …

Read More »

Gilead Announces Data Showing that States with Highest Use of Truvada for PrEP had Significant Declines in New HIV Infections

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) today announced results of a retrospective nationwide analysis of the impact of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) for pre-exposure prophylaxis (PrEP) use across all 50 U.S. states and the District of Columbia. Conducted in collaboration with researchers …

Read More »

Studies Show Two-Drug Regimen of Dolutegravir and Lamivudine Has Similar Efficacy to a Three-Drug Regimen in Treatment Naïve HIV Patients

  LONDON–(BUSINESS WIRE)–ViiV Healthcare today presented at the 22nd International AIDS conference in Amsterdam 48-week results from the phase III GEMINI 1 & 2 studies, assessing the safety and efficacy of a two-drug regimen (2DR) of dolutegravir (DTG) and lamivudine (3TC) compared to a three-drug regimen of dolutegravir and two nucleoside …

Read More »

FDA Approves Janssen’s Symtuza, the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV

TITUSVILLE, N.J., July 17, 2018 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved SYMTUZA™, the first and only complete, darunavir-based single-tablet regimen (STR) for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naïve and certain virologically suppressed adults. …

Read More »

Hookipa and Gilead Partner to Develop Immunotherapies Against HIV and Hepatitis B

Vienna, Austria and Foster City, CA, 5 June 2018 – Hookipa Biotech AG (“Hookipa”), a clinical-stage biotech company pioneering an innovative class of active immunization therapies for oncology and infectious diseases and Gilead Sciences, Inc., (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet …

Read More »

FDA Expands Approval of Gilead’s Truvada to Reduce the Risk of Acquiring HIV-1 in Adolescents

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)—in combination with safer sex practices—to reduce the risk of sexually acquired HIV-1 in at-risk adolescents. The safety and efficacy profile of Truvada …

Read More »

FDA Accepts NDAs for Merck’s Investigational NNRTI for Treatment of HIV-1 Infection

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two New Drug Applications (NDAs) for doravirine, the company’s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infection in adults. …

Read More »

FDA Approves Ortho Clinical Diagnostics’ HIV Combo Test on Immunodiagnostic System

RARITAN, N.J., Dec. 18, 2017 /PRNewswire/ — Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, announced that its VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator (VITROS® HIV Combo test) received approval from the U.S. Food and Drug Administration for use on Ortho’s VITROS 3600 Immunodiagnostic …

Read More »

CDC Report Finds Frequency of HIV Testing and Time from Infection to Diagnosis Improve

ATLANTA, Nov. 28, 2017 /PRNewswire-USNewswire/ — A new CDC Vital Signs report published today finds that HIV is being diagnosed sooner after infection than was previously reported. According to the report, the estimated median time from HIV infection to diagnosis was three years in 2015. CDC previously estimated that, in …

Read More »

FDA Approves ViiV Healthcare’s Juluca for Treatment of Patients with HIV

London, 21 November 2017 – ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has approved Juluca®, indicated as a complete regimen for the maintenance treatment of HIV-1 infection in adults who …

Read More »